Safety and Efficacy of Forodesine for a Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified with Liver Failure

Malignant lymphoma patients complicated with liver dysfunction is known for its difficulty in treatment. Forodesine is a purine nucleoside phosphorylase inhibitor approved in Japan for the treatment of peripheral T-cell lymphoma (PTCL), and its administration in liver failure patients are unknown. We experienced a 72-year-old woman with recurrent PTCL, not otherwise specified (NOS), and severe liver dysfunction caused by nonalcoholic steatohepatitis treated with forodesine. She remained in stable disease for six months by continuing forodesine, and no remarkable adverse effects occurred. Forodesine may be considered for PTCL patients complicated with severe liver dysfunction.

Keywords: peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), relapse, forodesine, liver failure.